Our Pipeline
VRTX126: KRAS-G12C Inhibitor
Discovery
Optimization
IND Enabling
Phase I
Colorectal Cancer
NSC Lung Cancer (NSCLC)
Lung cancer is the leading cause of cancer death for men and women worldwide. It is estimated that 236,740 adults will be diagnosed, and 130,180 deaths will occur in the United States from NSCLC. Worldwide, an estimated 2,206,771 people were diagnosed with lung cancer in 2020 (small cell lung cancer and NSCLC) and an estimated 1,796,144 people died worldwide from the disease. The 5-year relative survival rate is 22%.
VRTX153: KRAS-G12D Inhibitor
Discovery
Optimization
IND Enabling
Phase I
Pancreatic Cancer
In 2022, it was estimated that 62,210 adults will be diagnosed and 49,830 deaths will occur in the United States from pancreatic cancer. Worldwide it is estimated that 495,773 people were diagnosed and 466,003 deaths occured. It is the fourth leading cause of cancer death in both men and women. Pancreatic cancer accounts for 7% of all cancer deaths. 5-year relative survival rate for people with pancreatic cancer in the United States is 11%.
The KRAG12D mutation is considered to occur in about 35-40% of all pancreatic cancers and is high priority therapeutic target.
Other KRAS G12D Cancers
This mutation is estimated to occur in 12% of colorectal cancers and adenocarcinomas.
DNA Damage Response
Discovery
Optimization
IND Enabling
Phase I
DDR Pathway
The body’s response to endogenous or externally-triggered DNA damage can lead to dysregulated cell function and eventually cancer. A number of key proteins associated with the cell cycle checkpoints in the DDR pathway have been validated as significant targets for intervention. Direct inhibition of these pathways and the use of agents in combination with other oncogenic or immunological strategies are now understood as critical approaches in the fight against cancer.
RAS Pathway Targeting
Discovery
Optimization
IND Enabling
Phase I
Novel KRAS Approaches
RAS is one of the most well-defined proto-oncogenes and mutations in this protein are estimated to occur in upwards of 25% of all solid cancers. VRise is currently developing a series of drug like candidates targeting additional genetic alterations with existing programs in KRAS-G12V, R and S. VRise also expects to bring a diverse first-in-class opportunity using the PROTACs technology to drive the therapy with our inhibitor library.